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ABSTRACT

Non-communicable disease (NCD), in particular cardiovascular disease, is a
significant problem in developing countries. Essential hypertensions (EH) is a leading
risk factor for vascular disease and while managing EH in developing countries is
considered a high global priority, few studies exist from third world populations. From a
cohort of Kenyans living in the Kasigau region, we have investigated the allele frequency
of a single nucleotide polymorphism (SNP) previously reported to correlate with saltsensitive EH. The SNP being investigated is aldosterone synthase CYP11B2 C344T
(rs1799998), a polymorphism in the renin-angiotensin system (RAS). The C344T
polymorphism is located in the promoter region of CYP11B2 and affects the production
of aldosterone. In this study the overall allele frequency of T=0.81 and C=0.19, and the
genotype frequency was T/T=0.66, T/C=0.30, and C/C=0.04 for the total Kasigau
population in this study. There was no significant variance in blood pressure among any
of the three genotype.
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CHAPTER 1

INTRODUCTION

In 2008 the World Health Organization estimated that over 36 million deaths
occurred worldwide from non-communicable diseases (NCD). Out of the 57 millions
deaths that occurred worldwide, NCD were the leading cause of mortality at 63% (World
Health Organization, 2011). NCDs are diseases that cannot be transmitted from person to
person and include, cardiovascular disease (CVD), cancer, chronic respiratory disease,
stroke, and diabetes. NCD has been known to be the leading cause of pre-mature death in
people under 60 years old. In lower-middle-income countries NCD causes 28% of the
deaths of people under 60 years old, and in lower-income countries it causes 41% of the
pre-mature deaths under 60. One of the risk factors associated with NCD is essential
hypertension (EH) (World Health Organization, 2011).
EH is defined as high blood pressure without a known cause (Messerli &
Williams, 2007). EH is a worldwide concern because of its high frequency and link with
CVD (Kearney et al., 2005). EH has been found to be the leading risk factor for CVD
(Kobubo, 2014). Of the 39 million people that died of a NCD in 2008, 48% of those
deaths were linked to CVD (World Health Organization, 2011).
There are varying stages of hypertension classified as normotensive, prehypertension, stage 1 hypertension, and stage 2 hypertension. Blood pressure consists of
a systolic (resulting from ventricular contraction) measurement and diastolic (ventricular
1

relaxation) measurement, which is quantified in mmHg. Normal blood pressure is less
than or equal to 120/80 mmHg. Pre-hypertensive individuals have a blood pressure
between 121/81-139/89 mmHg. Stage 1 hypertension is classified as 140/90-159/99, and
stage 2 hypertension is classified as anything greater than 160/100. There is a direct
relationship between an increase in blood pressure and a greater risk for CVD.
EH is a complex polygenic disease that has been linked to many environmental
and hereditary factors in humans (Doris, 2002). Studies have shown that hypertension
has been connected to a collection of single nucleotide polymorphisms (SNPs) (Doris,
2002 & Kumar et al., 2003). A SNP is a common single nucleotide variation in the DNA
sequence of species. It has been found that single nucleotide variation can alter a person’s
susceptibility to hypertension (Doris, 2002).
When a polymorphism or SNP is identified it is referenced with a SNP ID, rs
number. An rs number is defined as a variation at a location on an ideal reference
chromosome and archived in the Single Nucleotide Polymorphism Database (dbSNP).
The database was developed and managed by the National Center for Biotechnology
Information of the National Institutes of Health. The specific SNP in this study is the
CYP11B2 C344T (rs1799998), which has been linked to EH in humans in other studies
(Kumar et al., 2003). CYP11B2 is an aldosterone synthase in the renin-angiontensin
system (RAS) (Kumar et al., 2003).
RAS is the key hormonal system in the body responsible for regulating blood
pressure and sodium homeostasis (Giner et al., 2000). It has a series of enzymes and
genes that are found throughout the body that can lead to elevating blood pressure (Figure
1). Angiotensinogen is secreted from the liver and broken down to angiotensin 1 by
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renin, and then converted to angiotensin II by angiotensin converting enzyme (ACE).
Angiotensin II is responsible for numerous physiological effects including the secretion
of hormone aldosterone from the adrenal cortex. Aldosterone in the RAS has been found
to control the reabsorption of ions and water in the kidney. As reabsorption of ions and
water increases blood pressure eventually resulting in hypertension. The C344T
polymorphism is located in the promotor region of the CYP11B2 gene and affects
aldosterone production because the gene encoder aldosterone synthase catalyzes the final
step in aldosterone biosynthesis (Kumar et al., 2003).

Figure 1: Renin-angiontensin system. The arrows indicate the hormonal pathway that can lead to
hypertension through Angiontensin II controlling the release of Aldosterone (Public Domain)

This study is based in Kenya, a sub-Saharan country in east Africa, with a
population of approximately 43 million people (World Health Organization, 2012).
About 75-80% of Kenyans live in a rural area on less than one US dollar per day (Unicef,
2014). The Kenyan health care system is a pyramid-like structure with only two national
3

referral hospitals. The rest of the country is divided into districts that have a few districtlevel hospitals and provincial clinics. Rural health centers and dispensaries provide most
of the primary health care (Figure 2). The health care system is government run by the
Ministry of Health and the Ministry of Public Health & Sanitation. On average there are
18 doctors per 100,000 people within the country (The World Health Organization,
2011). This is drastically different from the United States with on average 242 doctors
per 100,000 people (The World Health Organization, 2011).

Figure 2: Healthcare infrastructure in Kenya (Williams, 2012)

This study takes place in Kasigau, Kenya. Kasigau is located in the Taita-Taveta
District of southern Kenya. Kasigau is further divided into three sub-locations and seven
total villages (Figure 3). Sub-location Rukanga contains 29% of the population, and it
includes four villages: Rukanga, Jora, Ngambenyi, and Bungule. Sub-location
Makwasinyi makes up 21% of the total population spread across three villages:
Makwasinyi, Kisimenyi, and Kiteghe. The third sub-location is Buguta, which contains
50% of the Kasigau population (Census data, 2009). It has been found that through
previous research in our lab that there is a high prevalence of EH in Kasigau, Kenya
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compared to populations in the United States (Figure 4) (Williams, 2012; Wright et al.,
2011).

Figure 3: Kasigau, Kenya Sub-Locations (http://www.kids4kenya.org/TheSchools.php)

Through Western Kentucky University’s Partners in Caring: Medicine in Kenya
(PiC:MiK) program the health care concerns of hypertension within the Kasigau area are
met. PiC:MiK is a partnership between the people of Kasigau, Kenya and Western
Kentucky University. A team of approximately 20 people (3 doctors, 14 students, 1
faculty member, and 2 volunteers) travel to Kenya for two weeks to conduct medical
clinics and health care education through sustainable techniques and community oriented
work. PiC:MiK also offers the pre-professional students on the trip a first hand global
view of health care in a developing country. The 2014 visit was the sixth visit to Kenya
by this program in the last seven years. This thesis is a component of the research that is
focused on the cardiovascular health of the Kasigau people.
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The goal of this research project is to evaluate the prevalence of one SNP
(CYP11B2 C344T (rs1799998)) and its correlation to an increased risk of EH in Kasigau,
Kenya. It was hypothesized that the high prevalence of observed EH in Kasigau may be
linked to the CYP11B2 C344T polymorphism. This study will provide key genetic
information that will help prevent, treat, and/or control hypertension in Kenya and other
sub-Saharan countries.

Figure 4: EH Distribution in Kasigau, Kenya: The pie graph on the left shows the values for
systolic blood pressure, and the pie graph on the right shows the values for the diastolic blood
pressure. (Williams, 2012)
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CHAPTER 2

MATERIALS AND METHODS

Compliance/Informed Consent
This study was approved by Western Kentucky University’s Human Subjects
Review Board (Hr-174, Appendix A) and the Taita District Health Officer in Kenya
(Appendix B). All participants were read an informed consent document and their
willingness to participate in the study implied their consent (Appendix C).

Study Participants
Participants for this study were selected using a cross-sectional population
assessment of the Kasigau, Kenya using census data of the region. The area was
subdivided into sublocations: Rukanga, Makwasinyi, and Bughuta which comprise 29%,
21%, and 50% of the total population, respectively. Each sublocation includes one to
four villages in the Kasigau area.
Each participant was between the ages of 45-75 because of the increased risk of
EH in this age group. The goal was to have 50% of participants to be male and 50% of
participants to be nonpregnant females. However, 66% of the participants were female
and 34% were males. Overall, 400 individuals were recruited to take part in the study,
although only 161 of those individuals participated in the study.

7

Buccal Cell Acquisition
Buccal cells were acquired from participants using Isohelix DNA Buccal Cell
Swabs. These swabs were excellent to collect human genomic DNA because they can
yield up to 5 µg of DNA. The swabs were labeled by village and participants number in
order to correlate genotype data to an individual’s demographic data.
The collection of the buccal cells occurred during the participant’s clinic visit.
The individual’s cheek was swabbed thoroughly for one minute, and then the swabs were
sealed to avoid contamination. The samples were stored at 4oC until the DNA was
isolated.

Genomic DNA Isolation
Genomic DNA was isolated from swabs by standard alkaline lysis using the
QIAamp DNA Mini Kit (Qiagen; Valencia, CA, USA). Briefly, swabs were submerged
in phosphate buffered saline (PBS) in a microcentrifuge tube. Proteinase K and Buffer
AL were added and the samples were immediately vortexed for fifteen seconds to ensure
efficient lysis. Proteinase K was selected as the optimal enzyme with the lysis buffer
(Qiagen; Valencia, CA, USA). The samples were incubated at 56oC for ten minutes,
which activated the protease within each sample.
Subsequently ethanol (96-100%) was added to each sample, vortexed to ensure
proper mixing, then pipetted onto a spin column from the QIAamp DNA Mini Kit, and
centrifuged at 6,000 g, 1 minute to isolate genomic DNA. Columns were washed and
centrifuged with a series of wash buffers (AW1 and AW2) provided in the kit. The DNA
was extracted from the spin columns by the addition of buffer AE, by heating to 60oC.
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The columns were left to incubate with buffer AE in the tube for five minutes before they
were centrifuged at 6,000 g for one minute. The elution step was performed twice to
increase DNA yield. The two sets of DNA from each sample were stored at -20oC. All
genomic DNA was isolated from samples prior to quantification.

Nanodrop Analysis
DNA concentration and purity were determined by the ratio of absorbance of UV
light at 260/280 nm using a Nanodrop spectrophotometer (Thermo Scientific;
Wilmington, DE, USA). Two µl of each sample was analyzed to determine the final
DNA concentration.

Allelic Discrimination Analysis
Quantitative Polymerase Chain Reaction (Q-PCR) was used for genotype and
allelic discrimination, specifically by using the Taqman SNP Genotyping Assay Protocol
(Applied Biosystem; Foster City, CA, USA). This assay uses fluorescent dyes to
determine DNA binding. Each dye is covalently attached to a primer used in the PCR
reaction. A blue dye, 6FAM indicates the fluorescence of the G allele in the SNP. The
green dye, VIC indicates the fluorescence of the A allele in the SNP. Sequence Detection
System (SDS) software allowed the identification of the blue or green fluorescence
(Applied Biosystems; Foster City, CA, USA). A reporter dye and a quencher dye are
also found within the assay (Figure 5).
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Figure 5: Taqman® genotyping assay. (“Taqman® Genotyping Assay Product Bulletin,” Applied
Biosystems; Foster City, CA, USA).

All samples were run in triplicate on a MicroAmp® Optical 96-well reaction plate
(Applied Biosystems; Foster City, CA, USA) in an Applied Biosystem Prism 7300 RealTime polymerase chain reaction instrument. On each plate a negative control was
included that lacked DNA.
Each assay included 12.5 µl of a premade master mix, 1.25 µl of SNP assay,
11.25 µl of DNA and water, as well as 50 nM of forward primer labeled with VIC dye,
50 nM of reverse primer labeled with FAM dye, deoxyribonucleotides with deoxyuridine
triphosphates, AmpliTag Gold DNA polymerase, AmpErase® uracil-N-glycosylase,
optimized buffer, and passive reference components. The SNP’s context sequence is
provided in the table below.
SNP

Context Sequence

CYP11B2

TTTATCTTATCGTGAGATGAGAGGG[A/G]GCCTTGGATTCTTTTAA
TAGACTTT

rs1799998
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The cycling conditions were as follows: activation (95oC-10 minutes), denaturing (92oC15 seconds), extending and annealing (60oC-70 seconds). The cycling procedure was
repeated 50 times and was performed to sufficiently elevate the fluorescence for SDS to
detect within each well.
Fluorescence intensity for each sample was quantified through Q-PCR. Allele T
or C was determined based upon the values given from the fluorescence intensity.
Values below the no template control were eliminated from analysis.

Statistical Analysis
The Hardy-Weinburg Equilbrium (HWE) equation was used to determine if the
genotype and allelic frequencies observed were affected by any evolutionary influences.
The expected values of alleles were derived from observed data and analyzed using the
HWE equation (p2+2pq+q2=1). The p2 equals the frequency of the genotype T/T, the p
equals the frequency of allele T, the q2 equals the frequency of the genotype C/C, and the
q equals the frequency of allele C.
The genotype frequencies analyzed using a Pearson’s Chi Square test. The
equation

was used to determine significance of deviation in the genotype

frequencies and the HWE models. A Chi Square value was calculated in order to
determine if a frequency from each sublocation and in each hypertension classification
fell within HWE.
Variance of systolic blood pressure for each genotype was assessed by KruskalWallis one way Analysis of Variance on Ranks using Sigma Plot software.
11

CHAPTER 3

RESULTS

As a whole, approximately 81% of the Kasigau population possess the T allele,
while 19% possess the C allele of the CYP11B2 C344T SNP (Figure 6). Per sublocation
the C allele ranged from 13%-23% with Buguta having the lowest frequency. When the
allele frequencies were assessed as a genotype, it was found that Kasigau displayed 66%
T/T, 30% C/T, and 4% T/T (Figure 7). Makwasinyi had the highest distribution of C/C at
10%.
To assess whether allelic frequency varied based on the severity of EH, the
derived allelic and genotypic distribution of the SNP was determined for normotensive,
pre-hypertensive, Stage I EH, and Stage II EH, for the total Kasigau population as well as
the three sublocations. The EH classification was determined by using only the systolic
BP of participants. When the obtained genotype frequencies of the C344T SNP were
compared to the expected frequencies predicted by the HWE, all alleles were found to be
in HWE with the exception of pre-hypertensive people from Makwasinyi, (χ²=8.00,
p=0.04).
For all the sublocations and EH classifications T alleles were in greater frequency
than C alleles (Table 1). The T allele frequency for Kasigau as a whole, Buguta,
Makwasinyi, and Rukanga ranged from 78%-87%, while the C allele frequency ranged
from 13%-22%. The majority of the participants in the study had a genotype of T/T.
12

When variance in systolic blood pressure was analyzed among the three different
genotypes there was no significant difference among them, as determined by the
ANOVA, (p=0.78) (Table 2). The difference in the median values among the treatment
groups is not great enough to exclude the possibility that the difference is due to random
sampling variability. However, variance was not analyzed based on EH stage.
Based upon the results, the majority of the people of Kasigau possess the T allele
of the CYP11B2 C344T SNP. There is small variability in the frequency of the alleles
with the Kasigau participants who are normotensive vs the participants who have some
form of hypertensive. More statistical analysis will need to be done to confirm these
results.
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Figure 6: CYP11B2 allele frequencies for Kasigau
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Figure 7: CYP11B2 genotype distribution for Kasigau
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Rukanga

Table 1: CYP11B2 genotype distribution and allele frequencies per EH classification in Kasigau. HWE,
Hardy-Weinburg Equilibrium. *=p<0.05

Rukanga
N=48

Makwasinyi
N=31

Bughuta
N=26

Kasigau
N=105

Genotype
T/T
T/C
C/C
HWE
Allele
T
C
f (T)
f (C)
Genotype
T/T
T/C
C/C
HWE
Allele
T
C
f (T)
f (C)
Genotype
T/T
T/C
C/C
HWE
Allele
T
C
f (T)
f (C)
Genotype
T/T
T/C
C/C
HWE
Allele
T
C
f (T)
f (C)

Normotensive
6
2
1
χ²=1.15
p=0.28
Normotensive
14
3
0.82
0.18
Normotensive
0
0
0
χ²=ND
p=ND
Normotensive
0
0
0.00
0.00
Normotensive
3
0
0
χ²=ND
p=ND
Normotensive
6
0
1.00
0.00
Normotensive
9
2
1
χ²=1.92
p=0.17
Normotensive
20
4
0.83
0.17

Pre-hypertensive
10
6
0
χ²=0.85
p=0.36
Pre-hypertensive
26
6
0.81
0.19
Pre-hypertensive
7
0
1
χ²=8.00
p=0.04*
Pre-hypertensive
14
2
0.88
0.13
Pre-hypertensive
9
3
1
χ²=0.86
p=0.35
Pre-hypertensive
21
5
0.81
0.19
Pre-hypertensive
26
9
2
χ²=0.95
p=0.33
Pre-hypertensive
61
13
0.82
0.18
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Type 1 EH
5
5
1
χ²=0.02
p=0.87
Type 1 EH
15
6
0.71
0.29
Type 1 EH
5
3
1
χ²=0.26
p=0.61
Type 1 EH
13
5
0.72
0.28
Type 1 EH
5
1
0
χ²=0.05
p=0.82
Type 1 EH
11
1
0.92
0.08
Type 1 EH
15
9
2
χ²=0.15
p=0.69
Type 1 EH
39
13
0.75
0.25

Type 2 EH
8
4
0
χ²=0.48
p=0.49
Type 2 EH
20
4
0.83
0.17
Type 2 EH
11
2
1
χ²=2.43
p=0.12
Type 2 EH
24
4
0.86
0.14
Type 2 EH
3
1
0
χ²=0.08
p=0.77
Type 2 EH
7
1
0.88
0.13
Type 2 EH
22
7
1
χ²=0.22
p=0.64
Type 2 EH
51
9
0.85
0.15

Table 2: Variance in systolic blood pressure among genotype groups; H = 0.497 with 2 degrees of
freedom. (P = 0.780)

Group
T/T
T/C
C/C

N
73
30
7

16

Median
140.00
144.00
139.00

CHAPTER 4

DISCUSSION

In this study, the allelic and genotype frequencies of the CYP11B2 C344T SNP
known to influence predisposition to EH, was evaluated from a population in rural
Kasigau, Kenya. The allele frequencies were compared across normotensive,
prehypertensive, Stage I hypertensive, and Stage II hypertensive. Hypertension was
measured using only the participants’ systolic blood pressure. Overall, this work
investigates how polymorphic variation in a RAS gene influences phenotypic differences
of EH in Kasigau, Kenya.
There are many different approaches that exist for studying genetic associations
of complex diseases including genome-wide association studies, linkage disequilibrium,
and pooling strategies (Binder, 2006). The target gene approach was used in this study
because SNPs in the RAS genes have already been shown in other populations to
specifically correlate with an increase in susceptibility to EH (Tabor et al., 2002).
In our study all of the sublocation/EH classifications were found to be in HWE
except for the pre-hypertensive people from Makwasinyi, (χ²=8.00, p=0.04). These
results likely reflect limiting sample size although non-random mating may also be
contributing. This may be due to the physical location of this village on the opposite side
of the Kasigau Mountain, which contributes to its geographic isolation.
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It has been found in many studies that the CYP11B2 C344T SNP is associated
with EH, but there are differences regarding which allele is the susceptible allele
(Sookoian et al., 2007; Kumar et al., 2003; Tiago et al., 2003). Kumar’s research study
found that the C allele is the susceptible allele for EH in a Caucasian population. The
study also found that in participants who had both the C allele and EH, greater than 50%
were C/C homozygous. This was found to be significant for women who had EH (Kumar
et al., 2003). In the current study, the gender of the participants was not taken into
account during the analysis, although 56 of the participants had Stage I or Stage II
Hypertension. Out of those 56 participants 16 had the genotype T/C and 3 had the C/C
genotype. If a larger sample size were available it is possible that a greater amount of the
susceptible C allele may be present.
In contrast, a different study found that the T allele was correlated with an
increase in EH in people who were of African ethnicity (Tiago et al., 2003). In Tiago’s
(2003) study, it was also found that the T allele is more present in a South African
population. Sixty-six percent of participants in the current study had the T/T genotype.
Our study also showed that 88% of participants with the T/T genotype and 83% of
participants with the C/C genotype had EH. Taking into account that all the participants
in this study are of African ethnicity our data supports the conclusion of Tiago, et al
(2003). However, further research should be done to determine the genetic variation in
South Africans and East Africans. It should be noted that the ancestral allele is the T
allele. Most of the participants in our study with a form of EH had the T allele, however
there is no evidence to disregard the C allele as the susceptible allele. If a larger sample
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size were available it is possible that a greater amount of the susceptible C allele may be
present.
This study is one of the first to research a SNP related to EH in East Africans
(Freeman, 2013). The results in the future will be used to help promote awareness and
treatment for hereditary factors causing CVD and EH in developing countries. This study
also gave insight into how the genetic components of the RAS potentially affect the
development of EH in Kasigau, Kenya. Future research will also include epigenetic
factors, gene-gender interactions, aging effects, and salt sensitivity, which all have been
shown to be linked to EH in other studies (Deng, 2007; Hendriks et al., 2012).
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